-
PROVIDERS
Introducing the Immune Profile Score
Explore the science behind the IPS test, a prognostic biomarker for patients on ICI therapy
-
LIFE SCIENCES
Introducing the Immune Profile Score
Explore the science behind the IPS test, a prognostic biomarker for patients on ICI therapy
-
PATIENTS
It's About Time
View the Tempus vision.
- RESOURCES
-
ABOUT US
View Job Postings
We’re looking for people who can change the world.
- INVESTORS
Tempus IO™
A comprehensive immunotherapy platform that provides actionable and cutting-edge services for life sciences partners advancing IO therapies, including antibody-drug conjugates (ADCs), TCR therapies, and immune checkpoint inhibitors (ICIs).
An all-in-one biomarker platform
Comprehensive real-world data (RWD)
~99% of whole transcriptome profiles contain at least one IO biomarker
Robust suite of IO biomarkers
10+ IO biomarkers available through Tempus sequencing
Advanced analytical tech
Leverage AI- and ML-based analytical tools to unlock actionable insights
Immune Profile Score (IPS)
First-of-its-kind biomarker utilizing DNA and RNA to prognosticate ICI response
Insights delivered with every sample
Assess key aspects of the tumor microenvironment (TME) and understand resistance mechanisms using standard and novel biomarker data. Tempus IO data is included with applicable next-generation sequencing (NGS) assay orders to ensure comprehensive insights without the need for additional sample collection.
Download the Tempus IO overview to learn more-
Tempus xT: Solid Tumor DNA Seq
Tumor Mutational Burden (TMB)
Microsatellite Instability (MSI)
Neoantigen Prediction
Human Leukocyte Antigen (HLA) Typing
HLA Loss of Heterozygosity (LOH)
Oncogenic Virus
Mismatch Repair (MMR) Proteins by IHC1
PD-L1 Protein quantification by IHC1
Mechanisms of Tumor Resistance to Immunotherapy2
Immune Profile Score (IPS): ICI response prognosticator (available with concurrent xT and xR orders)
-
Tempus xE: Whole Exome
-
Tempus xR: Whole Transcriptome RNA Seq
Gene Expression Target Profiling3
Neoantigen Prediction
Immune Infiltration
Oncogenic Virus
T-cell Receptor / B-cell Receptor Repertoire
Mismatch Repair (MMR) Proteins by IHC1
PD-L1 Protein quantification by IHC1
Immune Profile Score (IPS): ICI response prognosticator (available with concurrent xT and xR orders)
-
Tempus xF/xF+: Liquid Biopsies
Tumor Mutational Burden (TMB)
Microsatellite Instability (MSI)
Neoantigen Prediction
Human Leukocyte Antigen (HLA) Typing
HLA Loss of Heterozygosity (LOH)
Oncogenic Virus
Mismatch Repair (MMR) Proteins by IHC1
PD-L1 Protein quantification by IHC1
Mechanisms of Tumor Resistance to Immunotherapy2
Immune Profile Score (IPS): ICI response prognosticator (available with concurrent xT and xR orders)
Tumor Mutational Burden (TMB)
Microsatellite Instability (MSI)
Neoantigen Prediction
Human Leukocyte Antigen (HLA) Typing
Oncogenic Virus
Mismatch Repair (MMR) Proteins by IHC1
PD-L1 Protein quantification by IHC1
Mechanisms of Tumor Resistance to Immunotherapy2
Gene Expression Target Profiling3
Neoantigen Prediction
Immune Infiltration
Oncogenic Virus
T-cell Receptor / B-cell Receptor Repertoire
Mismatch Repair (MMR) Proteins by IHC1
PD-L1 Protein quantification by IHC1
Immune Profile Score (IPS): ICI response prognosticator (available with concurrent xT and xR orders)
Go beyond sequencing with powerful analytics
Tempus’ analytical capabilities leverage AI and machine learning to enhance sequencing data, enabling the identification of potential biomarkers that correlate with therapy response. Our proprietary tools uncover novel cancer dependencies and drug targets, particularly in IO-resistant populations. Tempus also offers supplementary data, custom analyses, and specialized algorithms as add-ons to meet your specific research objectives.4
Discover Tempus Lens for in-depth data and insights
Understand ICI treatment response
Utilize Tempus’ Immune Profile Score (IPS), a first-of-its-kind multimodal algorithm that uses DNA and RNA to provide prognostic insights into potential outcomes following immune checkpoint inhibitor (ICI) treatment in metastatic solid tumors.
The algorithm generates a score that categorizes study participants into:
- IPS-High: Indicates a higher likelihood of favorable outcomes with ICI treatment.
- IPS-Low: Indicates a lower likelihood of favorable outcomes with ICI treatment.
Powering clinical development with data and technology
Tempus operates CAP-accredited, CLIA-certified robotic sequencing labs in Chicago, Atlanta, and Raleigh with automated bioinformatics and variant classification reporting. Sequencing is typically completed within a median of 8 days after receiving samples.
Download our lab overview
-
UPCOMING WEBINAR:
Clinical validation of a novel multi-omic algorithm for stratifying outcomes in a real-world cohort of metastatic solid cancer patients treated with immune checkpoint inhibitors
The Immune Profile Score (IPS) is a validated multi-omic biomarker that provides prognostic insights into ICI treatment outcomes in advanced cancer patients. IPS-high patients consistently show longer overall survival (OS) across various subgroups, highlighting its potential to identify those who benefit from ICI beyond existing biomarkers.
Read now -
UPCOMING WEBINAR:
Q&A: Advancing immunotherapy biomarker identification with Immune Profile Score (IPS)
Jason Blue-Smith, VP & GM of Algos at Tempus, discusses the challenges in immunotherapy biomarker identification and how Tempus’ Immune Profile Score (IPS) offers solutions to these problems.
Read now -
UPCOMING WEBINAR:
Detecting HLA loss of heterozygosity within a standard diagnostic sequencing workflow for prognostic and therapeutic opportunities
This study presents the development and validation of an assay to detect HLA loss of heterozygosity (LOH) within the FDA-approved Tempus xT CDx diagnostic test. The assay demonstrated high predictive accuracy and revealed significant prognostic implications for non-small cell lung cancer patients, facilitating its use in precision oncology for diagnostic, prognostic, and therapeutic applications.
Read now -
UPCOMING WEBINAR:
A multi-modal, pan-cancer atlas of tumor-immune states across primary and metastatic disease using a large, real-world database
In a pan-cancer analysis, significant differences in tumor immune states were observed by primary and metastatic sites, and by indication, with important implications for IO-treatment strategies. These data provide valuable and timely insights for IO research, where simultaneous assessment of molecular, immune, and clinical traits is required.
Read now -
UPCOMING WEBINAR:
Associations between multimodal immune biomarkers and clinical outcomes in a real-world non-small cell lung cancer cohort
Here we demonstrate that RNA-based immune signatures are significantly associated with clinical benefit and may supplement well-established ICI biomarkers in therapy selection. These immune RNA-based signatures need to be prospectively validated in future studies.
Read now
- Assessment of MMR proteins by IHC, including MLH1, MSH2, MSH6, and PMS2, as well as PD-L1 IHC, is available as an optional add-on for Tempus xT/xE orders. This service is not automatically included in every order and should be selected by the customer.
- Tempus provides information on multiple variants and features that have been reported to confer resistance to immunotherapy. This includes mutations and/or copy number alterations in immune-associated genes that affect antigen presentation or interferon signaling. (xT, xE only)
- Tempus performs RNA whole transcriptome sequencing when sufficient tissue samples are provided.
- The availability of supplementary data is dependent on the scope of the request.
Partner with us
With a broad range of laboratory services and data analysis that support immunotherapy development, Tempus has the solutions you need.